title: Surgical resection and outcome of pancreatic cystic neoplasms in China: analysis of a 16-year experience from a single high-volume academic institution.
abstract: BACKGROUND
  To investigate the clinicopathological features of surgically resected pancreatic cystic neoplasms (PCNs) at a single institution in China.
  
  
  METHODS
  The medical charts of patients who operated in the Second Affiliated Hospital, Zhejiang University School of Medicine between 1 January 1997 and 30 June 2013, were pathologically shown to have PCNs.
  
  
  RESULTS
  There was a reliable increase trend not just in the overall number of patients (3 to 75) but additionally in the number of incidentally diagnosed patients across the periods (33.3% to 48.0%). In 83 of 111 cases, preoperative diagnoses matched with pathology, whereas the remaining cases (16/28) were misdiagnosed as pancreatic cancer. The proportion of malignancy in mucin producing neoplasms was 24.3% (9 out of 37). Elevated serum carbohydrate antigen (CA19-9) or carcinoembryonic antigen (CEA) was independently associated with malignancy. The overall survival rate was 96.4%.
  
  
  CONCLUSIONS
  The proportion of PCNs within this series differs with that revealed in Western countries. Appropriate preoperative differential diagnosing of PCNs remains challenging. It is strongly recommended that patients with elevated CA19-9 or CEA levels undergo surgical resection.
authors.forename: Xueli
authors.initials: X
authors.lastname: Bai
authors.forename: Longyun
authors.initials: L
authors.lastname: Ye
authors.forename: Qi
authors.initials: Q
authors.lastname: Zhang
authors.forename: Pankaj
authors.initials: P
authors.lastname: Prasoon
authors.forename: Ji
authors.initials: J
authors.lastname: Wang
authors.affiliation: Department of Hepatobiliary-Pancreatic Surgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, 88 Jiefang St, Hangzhou 310009, Zhejiang, China. liangtingbo@zju.edu.cn.
authors.forename: Tingbo
authors.initials: T
authors.lastname: Liang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis*; D018395:CA-19-9 Antigen / Q000032:analysis; D002272:Carcinoembryonic Antigen / Q000032:analysis; D021441:Carcinoma, Pancreatic Ductal / Q000453:epidemiology / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D002681:China / Q000453:epidemiology; D018282:Cystadenocarcinoma, Mucinous / Q000453:epidemiology / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D018283:Cystadenocarcinoma, Papillary / Q000453:epidemiology / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D018284:Cystadenocarcinoma, Serous / Q000453:epidemiology / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000453:epidemiology / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D018395:CA-19-9 Antigen; D002272:Carcinoembryonic Antigen